Rhythm Pharmaceuticals, Inc.
RYTM
$90.51
$3.133.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 57.25M | 51.30M | 48.50M | 32.70M | 41.83M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 57.25M | 51.30M | 48.50M | 32.70M | 41.83M |
| Cost of Revenue | 4.80M | 5.50M | 5.54M | 3.65M | 3.79M |
| Gross Profit | 52.45M | 45.80M | 42.96M | 29.06M | 38.04M |
| SG&A Expenses | 57.48M | 52.43M | 45.95M | 39.09M | 38.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 104.32M | 103.95M | 93.80M | 79.71M | -9.32M |
| Operating Income | -47.06M | -52.65M | -45.30M | -47.00M | 51.15M |
| Income Before Tax | -47.54M | -52.79M | -46.30M | -49.42M | -43.38M |
| Income Tax Expenses | -31.00K | 111.00K | 337.00K | 80.00K | -90.00K |
| Earnings from Continuing Operations | -47.51M | -52.90M | -46.63M | -49.50M | -43.29M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.51M | -52.90M | -46.63M | -49.50M | -43.29M |
| EBIT | -47.06M | -52.65M | -45.30M | -47.00M | 51.15M |
| EBITDA | -46.79M | -52.35M | -44.92M | -46.62M | 51.53M |
| EPS Basic | -0.73 | -0.82 | -0.75 | -0.81 | -0.72 |
| Normalized Basic EPS | -0.44 | -0.50 | -0.45 | -0.49 | 0.50 |
| EPS Diluted | -0.73 | -0.82 | -0.75 | -0.81 | -0.72 |
| Normalized Diluted EPS | -0.44 | -0.50 | -0.45 | -0.49 | 0.50 |
| Average Basic Shares Outstanding | 66.88M | 66.26M | 63.68M | 63.06M | 61.60M |
| Average Diluted Shares Outstanding | 66.88M | 66.26M | 63.68M | 63.06M | 61.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |